11/13
01:09 am
lyra
Lyra Therapeutics GAAP EPS of -$3.38 beats by $0.98 [Seeking Alpha]
Low
Report
Lyra Therapeutics GAAP EPS of -$3.38 beats by $0.98 [Seeking Alpha]
11/12
04:27 pm
lyra
Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
11/12
04:01 pm
lyra
Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Low
Report
Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
10/6
07:10 am
lyra
Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study [Yahoo! Finance]
Medium
Report
Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study [Yahoo! Finance]
10/6
07:00 am
lyra
Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study
High
Report
Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study
10/3
03:40 pm
lyra
Lyra Therapeutics (NASDAQ:LYRA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Lyra Therapeutics (NASDAQ:LYRA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.